Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trastuzumab-AJICAP-maytansinoid
- Development stage
- Preclinical
- Lead developer
- Ajinomoto Bio-Pharma Services
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**trastuzumab-AJICAP-maytansinoid** is a preclinical, site-specific HER2-targeted antibody-drug conjugate developed using Ajinomoto's AJICAP Fc-affinity peptide conjugation technology. It couples trastuzumab to an MCC-maytansinoid cytotoxic payload in a more homogeneous configuration than stochastic trastuzumab emtansine conjugation. The ADC binds human epidermal growth factor receptor 2 on tumor cells, undergoes cellular uptake, and releases a maytansinoid-derived microtubule-disrupting payload. In published rat safety and HER2-positive NCI-N87 gastric cancer xenograft studies, it showed antitumor activity and a higher maximum tolerated dose than comparator trastuzumab emtansine. ([imrpress.com](https://www.imrpress.com/journal/FBL/27/8/10.31083/j.fbl2708234))
- Other names
- trastuzumab-AJICAP-maytansinoid
02
Targets
TUBB (Tubulin (alpha and beta subunits))ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on trastuzumab-AJICAP-maytansinoid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trastuzumab-AJICAP-maytansinoid.